Psyence Biomedical Ltd.
PBM
$0.5299
-$0.0034-0.64%
NASDAQ
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.92% | 47.31% | |||
| Depreciation & Amortization | 11.11% | 800.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.71% | 48.57% | |||
| Operating Income | -19.71% | -48.57% | |||
| Income Before Tax | -90.44% | 105.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -90.44% | 105.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -90.44% | 105.97% | |||
| EBIT | -19.71% | -48.57% | |||
| EBITDA | -19.73% | -48.43% | |||
| EPS Basic | -92.03% | 104.62% | |||
| Normalized Basic EPS | -63.10% | -78.51% | |||
| EPS Diluted | -92.05% | 104.62% | |||
| Normalized Diluted EPS | -63.09% | -78.48% | |||
| Average Basic Shares Outstanding | 19.94% | 29.24% | |||
| Average Diluted Shares Outstanding | 19.98% | 29.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||